Koers Wayland Group Corp. Canadian Securities Exchange
Aandelen
WAYL
CA9442041062
Farmaceutische producten
Omzet 2016 | 4,06 5,54 3,74 | Omzet 2017 | 3,22 4,4 2,97 | Marktkapitalisatie | 203 mln. 277 mln. 187 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2016 | -8 mln. -10,92 mln. -7,37 mln. | Nettowinst (verlies) 2017 | -67 mln. -91,44 mln. -61,74 mln. | EV/omzet 2016 * | - |
Nettoschuld 2016 | 9,13 12,46 8,41 | Nettoliquiditeiten 2017 | 0,42 0,57 0,39 | EV/omzet 2017 | 63.046.727 x |
K/w-verhouding 2016 * |
-
| K/w-verhouding 2017 |
-2,13
x | Werknemers | - |
Dividendrendement 2016 * |
-
| Dividendrendement 2017 |
-
| Vrij verhandelbaar | 100% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Ben Ward
CEO | Chief Executive Officer | 44 | - |
Dan Healey
COO | Chief Operating Officer | - | - |
Steven Bennett
CTO | Chief Tech/Sci/R&D Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Ben Ward
CEO | Chief Executive Officer | 44 | - |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+43,31% | 6,19 mld. | |
-16,99% | 4,48 mld. | |
+6,39% | 3,29 mld. | |
-13,10% | 3,12 mld. | |
-4,17% | 2,5 mld. | |
+45,47% | 1,94 mld. | |
-9,11% | 1,68 mld. | |
-2,09% | 1,64 mld. | |
-12,50% | 1,56 mld. |